CN115245522A - Method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide - Google Patents
Method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide Download PDFInfo
- Publication number
- CN115245522A CN115245522A CN202210834533.4A CN202210834533A CN115245522A CN 115245522 A CN115245522 A CN 115245522A CN 202210834533 A CN202210834533 A CN 202210834533A CN 115245522 A CN115245522 A CN 115245522A
- Authority
- CN
- China
- Prior art keywords
- supernatant
- hair
- umbilical cord
- proliferation
- oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006228 supernatant Substances 0.000 title claims abstract description 38
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 27
- 210000003780 hair follicle Anatomy 0.000 title claims abstract description 22
- 230000035755 proliferation Effects 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 12
- 230000003779 hair growth Effects 0.000 claims abstract description 13
- 206010061218 Inflammation Diseases 0.000 claims abstract description 12
- 210000004209 hair Anatomy 0.000 claims abstract description 12
- 230000004054 inflammatory process Effects 0.000 claims abstract description 12
- SKQIRRPTHXKMFU-UHFFFAOYSA-N N1(CCCC1)C1=[N+](C(=CC(=N1)N)N)[O-] Chemical compound N1(CCCC1)C1=[N+](C(=CC(=N1)N)N)[O-] SKQIRRPTHXKMFU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003102 growth factor Substances 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 8
- 210000004761 scalp Anatomy 0.000 claims description 7
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000004520 electroporation Methods 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 230000003676 hair loss Effects 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010015150 Erythema Diseases 0.000 claims description 3
- 206010040844 Skin exfoliation Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 230000035618 desquamation Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000003648 hair appearance Effects 0.000 claims description 3
- 230000009583 hair follicle growth Effects 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 239000002344 surface layer Substances 0.000 claims description 3
- 210000000106 sweat gland Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 2
- 210000004207 dermis Anatomy 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 14
- 239000000126 substance Substances 0.000 abstract description 6
- 102000004257 Potassium Channel Human genes 0.000 abstract description 3
- 210000001339 epidermal cell Anatomy 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 108020001213 potassium channel Proteins 0.000 abstract description 3
- 230000024883 vasodilation Effects 0.000 abstract description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 2
- 102000008186 Collagen Human genes 0.000 abstract description 2
- 108010035532 Collagen Proteins 0.000 abstract description 2
- 206010047141 Vasodilatation Diseases 0.000 abstract description 2
- 229920001436 collagen Polymers 0.000 abstract description 2
- 238000012258 culturing Methods 0.000 abstract description 2
- 229920002674 hyaluronan Polymers 0.000 abstract description 2
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 2
- 230000037070 skin defense Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 210000000963 osteoblast Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide, which belongs to the technical field of biotechnology, and is characterized in that the supernatant generated by culturing an osteoblast is rich in various growth factors, and is anti-inflammatory to hair follicles in inflammatory reaction, so that epidermal cells send out proliferation signals, the metabolism of the cells is promoted, and substances such as collagen, hyaluronic acid and the like can be promoted to be generated to form the integrity of a skin defense line while the proliferation of the epithelial cells is promoted, 3.5 percent pyrrolidinyl diaminopyrimidine oxide inhibits the hair from falling off, a potassium ion channel is opened through a vasodilatation mechanism around the hair follicle, nutrient substances for promoting the hair growth are diffused and enter, the longer hair growth period is promoted, the hair follicle is stimulated to regenerate, and healthy hair proliferation is formed.
Description
Technical Field
The invention relates to the technical field of biotechnology, in particular to a method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide.
Background
The main factor of alopecia is the excessive generation of dihydrotestosterone DHT, DHT can cause hair follicle death, hair loss and stimulation of sebaceous gland secretion to cause scalp inflammation, minoxidil is a hair growth chemical ingredient which is only approved by FDA, is a peripheral vasodilator, is originally used for treating hypertension patients, has the function of expanding blood vessels and is found to improve scalp blood circulation and nutrition supply, minoxidil can accelerate the metabolism cycle of hair follicles and enable hairs in a resting period to return to a new growth period, but has strong irritation to the scalp and possible side effects such as hypertension, pyrrolidinyl diaminopyrimidine oxide can effectively inhibit hair loss, can open potassium ion channels through a peripheral vasodilation mechanism of the hair follicles, can promote nutrient substances for hair growth to diffuse into the hair, can promote a longer hair growth period, can stimulate the regeneration of the hair follicles, cannot effectively inhibit scalp inflammatory reaction, particularly can generate plaques when skin is inflamed, and skin thread breakage and seepage can cause irritation increase to further to cause inflammation.
Based on the above, the present invention provides a method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide, so as to solve the above problems.
Disclosure of Invention
The invention aims to provide a method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide, so as to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a method of stimulating hair follicle proliferation with umbilical cord supernatant-combined oxide, said method of stimulating hair follicle proliferation with umbilical cord supernatant-combined oxide comprising the steps of:
(1) Collecting the supernatant produced in the umbilical cord cell preparation process, performing aseptic detection on the collected supernatant, packaging and freezing the supernatant to a refrigerator with the temperature of minus 20 ℃ after confirming no pollution, packaging the supernatant into a 2ML aseptic freezing tube, unfreezing and sampling the frozen liquid before the supernatant is taken out of the warehouse, confirming that the sample is aseptic, and then conveying the supernatant to a receiving point at a low temperature.
(2) The hair analyzer is used to confirm the alopecia part of the liquid to be introduced, and the electroporation introducing instrument is used to introduce the supernatant liquid, which is injected in the mode of electric pulse to form the penetrating path in the pores or sweat glands in the skin surface layer to reach the condition that the polymer enters into the hypodermis.
(3) The mixture of 3.5% pyrrolidinyl diaminopyrimidine oxide and umbilical cord cell supernatant is introduced in a manner of 2, the umbilical cord cell supernatant is a cell secretion rich in growth factors, the liquid is a product of the process of culturing cells in umbilical cord tissue, the mixture of umbilical cord cell supernatant is 3.5% of 8ML and 4ML, the mixture is filled into a special syringe of the instrument, and the mixture is introduced by using a nine-point probe of the instrument.
(4) And (3) observing the effect: in the second week after the introduction, the hair growth and appearance were followed after the first month, and the hair follicle growth and scalp inflammation were recorded.
(5) And (3) effect display: for the area with inflammatory reaction, the skin inflammation condition is reduced, desquamation, redness and allergic plaque are avoided, and fine hair growth is caused for the hair thin part.
Compared with the prior art, the invention has the beneficial effects that:
the invention utilizes the supernatant fluid generated by the culture of the cells to be rich in various growth factors, firstly resists inflammation for the hair follicle with inflammatory reaction, leads the epidermal cells to send proliferation signals, promotes the metabolism of the cells, promotes the proliferation of the epidermal cells, and simultaneously can promote the generation of substances such as collagen, hyaluronic acid and the like to form the integrity of skin defense lines, 3.5 percent of pyrrolidinyl diaminopyrimidine oxide inhibits the hair from falling off, leads a potassium ion channel to be opened through a mechanism of vasodilatation around the hair follicle, promotes the diffusion of nutrient substances for the hair growth, promotes the longer hair growth period, stimulates the hair follicle to regenerate and forms healthy hair hyperplasia.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The first embodiment is as follows:
the invention provides a technical scheme that: a method of stimulating hair follicle proliferation with umbilical cord supernatant-combined oxide, said method of stimulating hair follicle proliferation with umbilical cord supernatant-combined oxide comprising the steps of: (1) Collecting the supernatant produced in the umbilical cord cell preparation process, performing aseptic detection on the collected supernatant, packaging and freezing the supernatant to a refrigerator with the temperature of minus 20 ℃ after confirming no pollution, packaging the supernatant into a 2ML aseptic freezing tube, unfreezing and sampling the frozen liquid before the supernatant is taken out of the warehouse, confirming that the sample is aseptic, and then conveying the sample to a receiving point at a low temperature; (2) Firstly, confirming a hair loss part needing to be introduced with liquid by a hair analyzer, and then introducing supernate by using an electroporation introducing instrument, wherein the electroporation introducing instrument injects the supernate in an electric pulse mode, and utilizes pores or sweat glands on the surface layer of skin to form a penetration path so as to ensure that macromolecules enter the lower part of the dermis; (3) The mixture of 3.5 percent of pyrrolidinyl diaminopyrimidine oxide and umbilical cord cell supernatant is introduced in a mode of mixing the mixture according to the proportion of 2, the umbilical cord cell supernatant is cell secretion rich in growth factors, the liquid is a generation liquid of umbilical cord tissues in the cell culture process, the mixture of umbilical cord cell supernatant is 3.5 percent of 8ML and 4mL, the mixture is filled into a special injector of the instrument, and the nine-point probe of the instrument is used for introducing; (4) observation of effects: tracking hair growth and appearance, recording hair follicle growth and scalp inflammation in the second week after the introduction and after the first month; (5) success shows that: for the area with inflammatory reaction, the skin inflammation condition is reduced, desquamation, redness and allergic plaque are avoided, and fine hair growth is caused for the hair thin part.
In the description herein, references to the description of "one embodiment," "an example," "a specific example," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.
Claims (1)
1. A method for stimulating hair follicle proliferation by combining oxide with umbilical cord supernatant is characterized by comprising the following steps: the method for stimulating the proliferation of hair follicles by combining umbilical cord supernatant with oxide comprises the following steps:
(1) Collecting the supernatant produced in the umbilical cord adult cell preparation process, completing the aseptic detection of the collected supernatant, packaging and freezing the supernatant to a refrigerator with the temperature of minus 20 ℃ after confirming no pollution, packaging the supernatant into a 2ML aseptic freezing tube, unfreezing and sampling the frozen liquid before the supernatant is delivered out of the warehouse, confirming that the sample is aseptic, and then conveying the sample to a receiving point at a low temperature;
(2) Firstly, confirming a hair loss part of liquid to be led in by a hair analyzer, and then leading in supernatant by using an electroporation leading-in instrument, wherein the electroporation leading-in instrument injects the supernatant in an electric pulse mode, and utilizes pores or sweat glands on the surface layer of skin to form a penetration path so as to enable macromolecules to enter the lower part of the dermis;
(3) The mixture of 3.5 percent of pyrrolidinyl diaminopyrimidine oxide and umbilical cord cell supernatant is introduced in a mode of mixing the mixture according to the proportion of 2, the umbilical cord cell supernatant is cell secretion rich in growth factors, the liquid is a generation liquid of umbilical cord tissues in the cell culture process, the mixture of umbilical cord cell supernatant is 3.5 percent of 8ML and 4mL, the mixture is filled into a special injector of the instrument, and the nine-point probe of the instrument is used for introducing;
(4) And (3) observing the effect: tracking hair growth and appearance, recording hair follicle growth and scalp inflammation in the second week after the introduction and after the first month;
(5) And (3) effect display: for the area with inflammatory reaction, the skin inflammation condition is reduced, desquamation, redness and allergic plaque are avoided, and fine hair growth is caused for the hair thin part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210834533.4A CN115245522A (en) | 2022-07-16 | 2022-07-16 | Method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210834533.4A CN115245522A (en) | 2022-07-16 | 2022-07-16 | Method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115245522A true CN115245522A (en) | 2022-10-28 |
Family
ID=83699388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210834533.4A Pending CN115245522A (en) | 2022-07-16 | 2022-07-16 | Method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115245522A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070030690A (en) * | 2005-09-13 | 2007-03-16 | (주)아모레퍼시픽 | Cosmetic composition containing pyrrolidinyl diaminopyrimidine oxide |
| CN107550749A (en) * | 2017-10-15 | 2018-01-09 | 广州汀兰生物科技有限公司 | A kind of hair growth composition and its application |
| JP2019026573A (en) * | 2017-07-27 | 2019-02-21 | 株式会社古賀メディカルコンサルティング | Hair restorer |
-
2022
- 2022-07-16 CN CN202210834533.4A patent/CN115245522A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070030690A (en) * | 2005-09-13 | 2007-03-16 | (주)아모레퍼시픽 | Cosmetic composition containing pyrrolidinyl diaminopyrimidine oxide |
| JP2019026573A (en) * | 2017-07-27 | 2019-02-21 | 株式会社古賀メディカルコンサルティング | Hair restorer |
| CN107550749A (en) * | 2017-10-15 | 2018-01-09 | 广州汀兰生物科技有限公司 | A kind of hair growth composition and its application |
Non-Patent Citations (1)
| Title |
|---|
| VINCENZI C, MARISALDI B, TOSTI A, PATEL B.: "Effects of a New Topical Treatment Containing Several Hair Growth Promoters in Women with Early Female Pattern Hair Loss.", 《SKIN APPENDAGE DISORD.》, pages 146 - 151 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bazzano et al. | Topical tretinoin for hair growth promotion | |
| ES2023890B3 (en) | STIMULATION OF HAIR GROWTH. | |
| CN111214427B (en) | Acid-free skin refreshing composition, preparation method thereof and essence containing composition | |
| CN110742831B (en) | Brightening eye brightening and night-out eye mask essence and preparation method thereof | |
| CN114159336B (en) | Quick-dissolving bioremediation freeze-dried dressing and preparation method thereof | |
| CN113842334A (en) | Composition for promoting skin multi-dimensional defense and repair and preparation method thereof | |
| CN112043619B (en) | Peptide composition with repairing effect and preparation method and application thereof | |
| CN108619086A (en) | A kind of Cellular gels preparation for treating tissue damage and application thereof and the active gel solution of holding freeze-stored cell used | |
| CN109771322A (en) | Human stem cell factor skin repair composition and its application in skin care item | |
| CN115245522A (en) | Method for stimulating hair follicle proliferation by combining umbilical cord supernatant with oxide | |
| Griffin et al. | Increased factor XIIIa transglutaminase expression indermal dendrocytes after treatment with α-hydroxy acids: potential physiologic significance | |
| US20200164037A1 (en) | Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth | |
| CN112891517A (en) | Cytokine composition for promoting scalp hair follicle regeneration and preparation method and application thereof | |
| CN110840804A (en) | Hirudin mask cream for removing freckles and eliminating scars and repairing and preparation method thereof | |
| US11752087B2 (en) | Activated revitalizing lotion and preparation method and application thereof | |
| CN111773379A (en) | Injectable whitening wrinkle-removing preparation, preparation method and application thereof | |
| Widianingsih et al. | The efficacy and safety of fractional erbium YAG laser combined with topical amniotic membrane stem cell (AMSC) metabolite product for facial rejuvenation: A controlled, Split-Face Study | |
| CN110151677A (en) | Mescenchymal stem cell extract, extracting method and the application in terms of skin-tightening and anti-aging of gene modification | |
| Miyabe et al. | Kojic acid alters pheomelanin content in human induced pluripotent stem cell-derived melanocytes | |
| CN113908342A (en) | Stem cell composition applied to biological tissue repair and preparation method thereof | |
| US20230241121A1 (en) | Compositions and methods relating to exosomes derived from human dermal papilla cells | |
| Houshmand | Microneedling and Platelet‐Rich Plasma (PRP) | |
| US10947273B2 (en) | Peptides of use in the preventive and curative treatment of alopecia | |
| CN110038192A (en) | A method of facial freckle and chloasma are improved by water laser accunputure injection group | |
| CN117860642B (en) | Peptide-containing composition for repairing multiple skin barriers, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221028 |
|
| RJ01 | Rejection of invention patent application after publication |